Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
11
03
2024
accepted:
16
09
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
aheadofprint
Résumé
There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists. To establish unified international guidelines for the management of acneiform rash caused by EGFR inhibitors, based on an experts' Delphi consensus. The initiative was led by five members of the European Academy of Dermatology and Venereology Task Force 'Dermatology for Cancer Patients' who developed a questionnaire that was circulated to a group of 32 supportive oncodermatology experts in Europe, Canada, Argentina, the US States and Asia. The questionnaire consisted of 84 statements in total, regarding diagnosis and treatment of EGFRi-induced acneiform rash. Experts responded to an anonymous 5-point Likert scale survey. The coordinators collected the first-round responses that were checked for consensus (≥75% agreement in positive [agree or strongly agree] or in negative [disagree or strongly disagree] vote). The statements that did not reach strong consensus in the first round were revised, according to experts' feedback, for a second-round survey. Strong consensus was reached in 75/84 (89.3%) of the statements, whilst moderate consensus was achieved in 6/84 elements. Key points include consideration of low-dose isotretinoin for refractory grade II/III acneiform rash, use of topical steroid-sparing agents like topical pimecrolimus in the maintenance phase and use of doxycycline in either 100 or 200 mg per day as prophylactic treatment. Interestingly, experts did not recommend topical antibiotics, neither for prevention, nor for treatment. Consensus failure in 3/84 objects is mostly related to the lack of robust data on these topics. This consensus offers crucial insights often overlooked by radiotherapists, general practitioners, dermatologists and oncologists, and it is expected to improve the management of oncologic patients treated with EGFRi in different settings and continents.
Sections du résumé
BACKGROUND
BACKGROUND
There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists.
OBJECTIVE
OBJECTIVE
To establish unified international guidelines for the management of acneiform rash caused by EGFR inhibitors, based on an experts' Delphi consensus.
METHODS
METHODS
The initiative was led by five members of the European Academy of Dermatology and Venereology Task Force 'Dermatology for Cancer Patients' who developed a questionnaire that was circulated to a group of 32 supportive oncodermatology experts in Europe, Canada, Argentina, the US States and Asia. The questionnaire consisted of 84 statements in total, regarding diagnosis and treatment of EGFRi-induced acneiform rash. Experts responded to an anonymous 5-point Likert scale survey. The coordinators collected the first-round responses that were checked for consensus (≥75% agreement in positive [agree or strongly agree] or in negative [disagree or strongly disagree] vote). The statements that did not reach strong consensus in the first round were revised, according to experts' feedback, for a second-round survey.
RESULTS
RESULTS
Strong consensus was reached in 75/84 (89.3%) of the statements, whilst moderate consensus was achieved in 6/84 elements. Key points include consideration of low-dose isotretinoin for refractory grade II/III acneiform rash, use of topical steroid-sparing agents like topical pimecrolimus in the maintenance phase and use of doxycycline in either 100 or 200 mg per day as prophylactic treatment. Interestingly, experts did not recommend topical antibiotics, neither for prevention, nor for treatment. Consensus failure in 3/84 objects is mostly related to the lack of robust data on these topics.
CONCLUSION
CONCLUSIONS
This consensus offers crucial insights often overlooked by radiotherapists, general practitioners, dermatologists and oncologists, and it is expected to improve the management of oncologic patients treated with EGFRi in different settings and continents.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 European Academy of Dermatology and Venereology.
Références
Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007;117(8):2051–2058.
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
Zubair T, Bandyopadhyay D. Small molecule EGFR inhibitors as anti‐cancer agents: discovery, mechanisms of action, and opportunities. Int J Mol Sci. 2023;24(3):2651.
Yan L, Beckman RA. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques. 2005;39(4):565–568.
Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–812.
Fabbrocini G, Panariello L, Caro G, Cacciapuoti S. Acneiform rash induced by EGFR inhibitors: review of the literature and new insights. Ski Appendage Disord. 2015;1(1):31–37.
Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008;58(4):545–570.
Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high‐grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer. 2009;115(6):1286–1299.
Eilers RE, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. JNCI J Natl Cancer Inst. 2010;102(1):47–53.
Sangaré L, Divita A, Rehn M, McNamara M, Lowe KA. Navigating metastatic colorectal treatment options in the USA: a survey of patient acceptance of skin toxicities associated with Vectibix. Support Care Cancer. 2021;29(11):6731–6740.
Barbu MA, Niţipir C, Voiosu T, Giurcăneanu C. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single‐center prospective study. Rom J Intern Med. 2018;56(2):96–101.
Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–333.
Ra HS, Shin SJ, Kim JH, Lim H, Cho BC, Roh MR. The impact of dermatological toxicities of anti‐cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatology Venereol. 2013;27:27(1).
Gorji M, Joseph J, Pavlakis N, Smith SD. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: a systematic review and meta‐analysis. Asia Pac J Clin Oncol. 2022;18(6):526–539.
Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor‐associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–1095.
Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fernández‐Peñas P, Santini D, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice guidelines☆. Ann Oncol. 2021;32(2):157–170.
Kikuchi K, Yamazaki N, Nozawa K, Fukuda H, Shibata T, Machida R, et al. Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, col). Support Care Cancer. 2022;30(5):4497–4504.
Nishino K, Fujiwara Y, Ohe Y, Saito R, Miyauchi E, Kobayashi T, et al. Results of the non‐small cell lung cancer part of a phase III, open‐label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH‐1512). Support Care Cancer. 2021;29(5):2327–2334.
Yamada M, Iihara H, Fujii H, Ishihara M, Matsuhashi N, Takahashi T, et al. Prophylactic effect of Oral minocycline in combination with topical steroid and skin care against Panitumumab‐induced acneiform rash in metastatic colorectal cancer patients. Anticancer Res. 2015;35(11):6175–6181.
Basse C, Chabanol H, Bonte PE, Fromantin I, Girard N. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non‐small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. Lung Cancer. 2022;173:116–123.
Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with Panitumumab (STEPP), a phase II, open‐label, randomized trial evaluating the impact of a pre‐Emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351–1357.
Liu HB, Wu Y, Lv TF, Yao YW, Xiao YY, Yuan DM, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non‐small cell lung cancer: a systematic review and meta‐analysis. PLoS One. 2013;8(1):e55128.
Gerber PA, Meller S, Eames T, Buhren BA, Schrumpf H, Hetzer S, et al. Management of EGFR‐inhibitor associated rash: a retrospective study in 49 patients. Eur J Med Res. 2012;17(1):4.
Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of Tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist. 2012;17(4):555–568.
Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, et al. Systemic doxycycline for pre‐emptive treatment of anti‐EGFR‐related skin toxicity in patients with metastatic colorectal cancer receiving first‐line panitumumab‐based therapy: a post hoc analysis of the Valentino study. Support Care Cancer. 2021;29(7):3971–3980.
Grande R, Narducci F, Bianchetti S, Mansueto G, Gemma D, Sperduti I, et al. Pre‐emptive skin toxicity treatment for anti‐EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study. Support Care Cancer. 2013;21(6):1691–1695.
Melosky B, Anderson H, Burkes RL, Chu Q, Hao D, Ho V, et al. Pan Canadian rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor‐tyrosine kinase inhibitor–induced skin toxicities in patients with metastatic lung cancer. J Clin Oncol. 2016;34(8):810–815.
Lacouture ME. Taking it in the chin: vitamin K1 for the prevention of acneiform rash. Ann Oncol. 2018;29(4):796–798.
Brown J, Su Y, Nellesen D, Shankar P, Mayo C. Management of epidermal growth factor receptor inhibitor‐associated rash: a systematic review. J Community Support Oncol. 2016;14(1):21–28.
Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic toxicity occurring during anti‐EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review. Clin Colorectal Cancer. 2018;17(2):85–96.
Peng Y, Li Q, Zhang J, Shen W, Zhang X, Sun C, et al. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. Biosci Trends. 2018;12(6):537–552.
Bachmeyer C, Reguiaï Z, Peuvrel L, Bachet JB, Bensadoun RJ, Ychou M, et al. Toxicité cutanée des anti‐EGFR (epidermal growth factor receptor) : algorithme thérapeutique du groupe français PROCUR. Bull Cancer. 2013;100(5):417–426.
Baas JM, Krens LL, Guchelaar HJ, Ouwerkerk J, de Jong F, Lavrijsen APM, et al. Recommendations on management of EGFR inhibitor‐induced skin toxicity: a systematic review. Cancer Treat Rev. 2012;38(5):505–514.
Kripp M, Prasnikar N, Vehling‐Kaiser U, Quidde J, Al‐Batran SE, Stein A, et al. AIO LQ‐0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab‐mediated skin toxicity in patients with metastatic colorectal cancer. Oncotarget. 2017;8(62):105061–105071.
Likert R. A technique for the measurement of attitudes. Arch Psychol. 1932;140:1–55.
Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74(9):979–983.
Clayton MJ. Delphi: a technique to harness expert opinion for critical decision‐making tasks in education. Educ Psychol. 1997;17(4):373–386.
Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008–1015.
Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol. 2021;11(4):116–129.
Taylor E. We agree, Don't we? The Delphi method for health environments research. HERD Heal Environ Res des J. 2020;13(1):11–23.
Hirotsu K, Dang TM, Li S, Neal JW, Pugliese S, Subramanian A, et al. Association of Antibiotic Resistance with Antibiotic use for epidermal growth factor receptor inhibitor–related Papulopustular eruption. JAMA Dermatol. 2019;155(7):848–850.
Sibaud V, Tournier E, Roché H, Del Giudice P, Delord JP, Hubiche T. Late epidermal growth factor receptor inhibitor‐related papulopustular rash: a distinct clinical entity. Clin Exp Dermatol. 2016;41(1):34–37.
Braden RL, Anadkat MJ. EGFR inhibitor‐induced skin reactions: differentiating acneiform rash from superimposed bacterial infections. Support Care Cancer. 2016;24(9):3943–3950.
Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, et al. The development of a functional assessment of cancer therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT‐EGFRI‐18). Support Care Cancer. 2013;21(4):1033–1041.
Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, et al. A prospective randomized trial of topical pimecrolimus for cetuximab‐associated acne‐like eruption. J Am Acad Dermatol. 2009;61(4):614–620.
Nikolaou V, Stratigos A, Antoniou C, Kiagia M, Nikolaou C, Katsambas A, et al. Pimecrolimus cream 1% for the treatment of Papulopustular eruption related to epidermal growth factor receptor inhibitors: a Case series and a literature review of therapeutic approaches. Dermatology. 2010;220(3):243–248.
Costello CM, Hill HE, Brumfiel CM, Yang YW, Swanson DL. Choosing between isotretinoin and acitretin for epidermal growth factor receptor inhibitor and small molecule tyrosine kinase inhibitor acneiform eruptions. J Am Acad Dermatol. 2021;84(3):840–841.
Andrews ED, Garg N, Patel AB. A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor– and mitogen‐activated protein kinase kinase inhibitor–induced acneiform eruptions. J Am Acad Dermatol. 2020;82(4):998–1000.
Lu C, Pang JS, Ko Y, Chang C, Wang C, Chen W, et al. Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma. J Eur Acad Dermatology Venereol. 2023;37(2):328–339.
Jaka A, Gutiérrez‐Rivera A, López‐Pestaña A, del Alcázar E, Zubizarreta J, Vildosola S, et al. Factores predictores de respuesta y revisión de la toxicidad cutánea de cetuximab y panitumumab en 116 pacientes. Actas Dermosifiliogr. 2015;106(6):483–492.
Aw DC, Tan EH, Chin TM, Lim HL, Lee HY, Soo RA. Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities. Asia Pac J Clin Oncol. 2018;14(1):23–31.
Sinclair R. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors. Asia Pac J Clin Oncol. 2014;10(S1):11–17.
Belum VR, Marchetti MA, Dusza SW, Cercek A, Kemeny NE, Lacouture ME. A prospective, randomized, double‐blinded, split‐face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab‐induced acneiform rash. J Am Acad Dermatol. 2017;77(3):577–579.
Scope A, Agero ALC, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double‐blind trial of prophylactic Oral minocycline and topical Tazarotene for Cetuximab‐associated acne‐like eruption. J Clin Oncol. 2007;25(34):5390–5396.
Chayahara N, Mukohara T, Tachihara M, Fujishima Y, Fukunaga A, Washio K, et al. Adapalene gel 0.1% versus placebo as prophylaxis for anti‐epidermal growth factor receptor‐induced acne‐like rash: a randomized left‐right comparative evaluation (APPEARANCE). Oncologist. 2019;24(7):885‐e413.
Vaccaro M, Guarneri F, Borgia F, Pollicino A, Altavilla G, Cannavò SP. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab‐associated acneiform eruption in patients with metastatic colorectal cancer. J Dermatolog Treat. 2016;27(2):148–152.
Katzer K, Tietze J, Klein E, Heinemann V, Ruzicka T, Wollenberg A. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR‐inhibitor cetuximab – a report of 29 patients. Eur J Dermatology. 2010;20(1):82–84.
Hofheinz RD, Lorenzen S, Trojan J, Ocvirk J, Ettrich TJ, Al‐Batran SE, et al. EVITA—a double‐blind, vehicle‐controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab‐induced skin toxicity. Ann Oncol. 2018;29(4):1010–1015.
Hashimoto H, Iwasa S, Yanai‐Takahashi T, Honma Y, Kato K, Hamaguchi T, et al. Randomized, double‐blind, placebo‐controlled phase II study on the efficacy and safety of vitamin K1 ointment for Cetuximab or Panitumumab‐induced acneiform eruptions‐VIKTORIA study. Gan To Kagaku Ryoho. 2020;47(6):933–939.
Jo JC, Hong YS, Kim KP, Lee JL, Kim HJ, Lee MW, et al. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Eur J Dermatology. 2013;23(1):77–82.
Perez‐Soler R, Zou Y, Li T, Ling YH. The phosphatase inhibitor Menadione (vitamin K3) protects cells from EGFR inhibition by Erlotinib and Cetuximab. Clin Cancer Res. 2011;17(21):6766–6777.
Amitay‐Laish I, Prag‐Naveh H, Ollech A, Davidovici B, Leshem YA, Snast I, et al. Prophylactic topical treatment for EGFR inhibitor‐induced Papulopustular rash: a randomized clinical trial. Dermatology. 2021;237(6):988–994.
Bierbrier R, Lam M, Pehr K. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors. Dermatol Ther. 2022;35(5):e15412.